October 9th, 2026FDA Approves Once-Monthly Subcutaneous Olanzapine for SchizophreniaWeltruza requires no loading doses, oral supplementation, or post-injection monitoring, with approval based on the phase 3 SOLARIS trial.Read more
October 5th, 2026Q3 2026 Recap: Psychiatry News and UpdatesCentanafadine's ADHD approval, the MDMA NDA resubmission, DT120 phase 3 wins, and the FDA psychedelic hearing headline Q3 2026 psychiatry news.Read more